Aalto Bio Reagents

COVID 19 Profile:

In early 2020, Aalto Bio launched the first recombinant SARS-COVID 19 Nucleocapsid Protein for diagnostic test manufacturers, vaccine developers and researchers globally. The Nucleocapsid protein plays a fundamental role during vaccine assembly through its interactions with the viral genome and membrane protein M, and it also plays a vital part in enhancing the efficiency of subgenomic viral RNA transcription, as well as viral replication.

While patients are currently screened for COVID 19 by PCR (polymerase chain reaction), serological tests are successful in detecting mild or asymptomatic cases that could otherwise be missed. Sero-epidemiologic investigations such as those aimed at better understanding of the transmission characteristics and severity of COVID-19 are also essential in getting a better understanding of the virus.  Having launched in February this year, Aalto’s COVID-19 proteins are already being utilised by international clients in the medical and diagnostic sectors.


Aalto Bio Profile:

Aalto Bio Reagents has been at the forefront in the supply of raw materials to the global diagnostics market since it was founded in 1978.  Based in Rathfarnham, Dublin we work in close partnership with our customers, enabling them to bring superior, best of class products to market quickly. Our products are now in use in both global multinationals, specialist developers of diagnostic products and research laboratories in world class universities.

At Aalto, one of our key strengths is our ability to respond quickly to market demand, and we are continuously expanding our product portfolio in response to disease outbreaks. Following on the emergence of the current COVID-19 pandemic, our previous experience in the ever-changing tropical disease sector, enabled us to work quickly to launch the first recombinant SARS-COV-2 Nucleocapsid protein to the market.  These proteins are already being harnessed by our international clients as they endeavour to respond to the COVID-19 crisis.

COVID landing page


COVID product page


COVID announcement page